Literature DB >> 10233761

Prevalence and antigen specificity of anti-histone antibodies in patients with polymyositis/dermatomyositis.

M Kubo1, H Ihn, N Yazawa, S Sato, K Kikuchi, K Tamaki.   

Abstract

Anti-histone antibodies have been detected in the sera of patients with various autoimmune diseases. The existence of anti-histone antibodies in patients with polymyositis/dermatomyositis, however, has not been reported. We found anti-histone antibodies in eight (17%) of 46 sera from patients with polymyositis/dermatomyositis by an enzyme-linked immunosorbent assay. One serum was positive for both IgG anti-histone antibodies and IgM anti-histone antibodies. Six sera were positive only for IgG anti-histone antibodies. One serum was positive only for IgM anti-histone antibodies. An indirect immunofluorescence analysis using HEp-2 cells as the substrate showed that all sera positive for anti-histone antibodies produced homogeneous nuclear fluorescence. This immunofluorescence pattern disappeared after absorption of anti-histone activity with total histones. An immunoblotting analysis demonstrated that the anti-histone antibodies were predominantly directed against histone H1 in all seven sera with IgG anti-histone antibodies. Weak reactivity with H2B and H4 were also found in three sera from the patients with polymyositis/dermatomyositis. Sera from two patients with polymyositis/dermatomyositis displayed anti-H2A and H3 activity. One of the two sera showed IgM anti-histone antibodies in the enzyme-linked immunosorbent assay reacted with H1, H2A, H2B, H3, and H4, whereas the other serum reacted with no fractions of total histones. The activity of anti-histone antibodies disappeared in immunoblotting after absorption with total histones. All of the patients with anti-histone antibodies were free from lung fibrosis or internal malignancies. Thus, our data indicate that the presence of anti-histone antibodies is classified as one of the serologic abnormalities observed in polymyositis/dermatomyositis.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10233761     DOI: 10.1046/j.1523-1747.1999.00580.x

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  6 in total

1.  Prevalence in myositis of antibodies recognizing anti-U3 RNA probably in a novel complex with 22/25 kD protein and not fibrillarin.

Authors:  M Kubo; H Ihn; M Kuwana; K Yamane; N Yazawa; K Tamaki
Journal:  Clin Exp Immunol       Date:  2001-11       Impact factor: 4.330

2.  The sera from adult patients with suggestive signs of autoimmune diseases present antinuclear autoantibodies that cross-react with Leishmania infantum conserved proteins: crude Leishmania histone and Soluble Leishmania antigens [corrected].

Authors:  Sami Lakhal; Meriem Benabid; Ines Ben Sghaier; Jihen Bettaieb; Aïda Bouratbine; Yousr Galai
Journal:  Immunol Res       Date:  2015-02       Impact factor: 2.829

3.  Anti-histones antibodies in systemic lupus erythematosus: prevalence and frequency in neuropsychiatric lupus.

Authors:  Xiao-Yun Sun; Jinxia Shi; Lei Han; Yin Su; Zhan-Guo Li
Journal:  J Clin Lab Anal       Date:  2008       Impact factor: 2.352

4.  Antigen specificity of antihistone antibodies in connective tissue disease patients with anti-U1RNP antibodies.

Authors:  Takamasa Wayaku; Minoru Hasegawa; Kenzo Kaji; Miki Kondo; Yuki Saito; Hidemitsu Orito; Mayuka Horikawa; Takashi Matsushita; Kazuhiro Komura; Ikuko Hayakawa; Yasuhito Hamaguchi; Fumihide Ogawa; Manabu Fujimoto; Kazuhiko Takehara; Shinichi Sato
Journal:  Rheumatol Int       Date:  2007-07-13       Impact factor: 2.631

Review 5.  Idiopathic inflammatory myopathy: autoantibody update.

Authors:  Ira N Targoff
Journal:  Curr Rheumatol Rep       Date:  2002-10       Impact factor: 4.592

6.  A rare case of suspected lupus erythematous panniculitis as the presenting skin feature of juvenile dermatomyositis: A case report.

Authors:  Dylan C Ginter; Michele L Ramien; Marie-Anne Brundler; Laura C Swaney; Paivi Mh Miettunen; Nadia Jc Luca
Journal:  SAGE Open Med Case Rep       Date:  2022-03-25
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.